Exelon - Rivastigmine

Exelon is a rivastigmine-containing medicine prescribed for dementia symptoms in Alzheimer’s disease and Parkinson’s disease dementia. It does not cure the underlying disease, yet it can help some patients maintain cognition and day-to-day activities for longer.

Exelon, containing the active ingredient rivastigmine, is a medicine used to treat dementia linked to Alzheimer’s disease and Parkinson’s disease.

Dosing is individualised and is usually titrated upward in steps to reduce stomach side effects and dizziness. This is one of those medicines where “start low, go slow” is not a slogan—it prevents dropouts from nausea.

Typical administration approach for capsules:

• Taken with food, usually morning and evening.
• Dose increases are separated by weeks, not days.
• If treatment is interrupted for several days, clinicians often restart at a lower dose and re-titrate rather than resuming the previous dose.

Missed dose rules used in practice:

• If a dose is missed, take the next scheduled dose at the usual time.
• Avoid doubling the next dose, since that raises the risk of vomiting, fainting, and slow heart rate.

Some sources describe Exelon as requiring a physician’s prescription for safe titration and monitoring, even when local dispensing rules vary ^[2].

• Route: oral tablets; take by mouth.
• Dose: start with 1.5 mg twice daily, then increase to 3 mg twice daily, 4.5 mg twice daily, and 6 mg twice daily if tolerated.
• Frequency: 2 times/day.
• Timing: take with food, preferably with the morning and evening meals.
• Duration: continue daily long term as prescribed; dose changes are usually made every at least 2 weeks based on tolerability.

Exelon is a rivastigmine-containing medicine prescribed for dementia symptoms in Alzheimer’s disease and Parkinson’s disease dementia. It does not cure the underlying disease, yet it can help some patients maintain cognition and day-to-day activities for longer.

People shopping for Exelon often want to understand how rivastigmine fits against other dementia medicines. The key difference is mechanism and tolerability profile, not “stronger vs weaker”.

Rivastigmine’s “two-enzyme” inhibition is a pharmacology detail many patients never hear, yet it explains why response can differ between rivastigmine and donepezil even though both are in the same broad class. Memantine tends to be used later in the disease course, and it does not share the same nausea-and-weight-loss pattern as strongly.

These are patterns pharmacists see repeatedly with Exelon capsules:

• Stopping after 2–3 days because of nausea, without trying food timing or slower titration.
• Restarting at the old dose after a gap of several days, which often triggers intense vomiting and dizziness.
• Taking doses on an empty stomach to “absorb better”, then blaming the medicine for intolerance.
• Ignoring fainting, new slow pulse, or black stools, assuming they are “just age-related”.
• Mixing up “memory seemed worse” during an intercurrent illness (UTI, dehydration, poor sleep) with medicine failure and escalating doses too quickly.

A final real-world point: if weight loss begins, clinicians take it seriously. It can be a direct drug effect (less appetite, more nausea) or a sign the patient needs more feeding support.